From SBA-backed full cash at close to earnouts tied to client retention rates, understand the deal structures that protect buyers and motivate sellers in RCM company transactions.
Acquiring or selling a medical billing company in the $1M–$5M revenue range involves deal structures that reflect the industry's unique risk profile: recurring but relationship-dependent revenue, compliance-sensitive operations, and significant key-person exposure. Unlike asset-heavy businesses, a medical billing company's value sits almost entirely in client contracts, certified staff, and billing software integrations — all of which are difficult to verify and easy to lose during an ownership transition. Buyers financing with SBA 7(a) loans typically cover 80–90% of the purchase price while requiring seller participation through a note or equity rollover. Strategic acquirers and PE-backed roll-ups often layer in earnout provisions tied to client retention and net collection rate performance over 12–24 months post-close. Understanding how these structures interact with HIPAA compliance obligations, payer audit exposure, and client concentration risk is essential for both sides to close a deal that holds together after the ink dries. Valuation multiples for well-run medical billing companies typically range from 3.5x to 6x EBITDA, with structure often bridging the gap between buyer and seller price expectations.
Find Medical Billing Company Businesses For SaleFull Cash at Close with SBA 7(a) Financing
The buyer secures an SBA 7(a) loan covering 80–90% of the purchase price, with the seller receiving full payment at closing. The seller may carry a small subordinated note of 5–10% required by the SBA lender to demonstrate confidence in the business. This is the most common structure for individual operator buyers acquiring a medical billing company under $5M in revenue.
Pros
Cons
Best for: Owner-operators retiring after 15–25 years who want a clean exit and have a diversified client base with documented contracts and clean HIPAA compliance history.
Partial Earnout Tied to Client Retention and Revenue Thresholds
A portion of the purchase price — typically 15–25% — is deferred and paid over 12–24 months based on whether the business retains specified clients and hits revenue or collection rate benchmarks. This structure is common when client concentration risk is elevated or when the seller's relationships are central to the business's ongoing performance.
Pros
Cons
Best for: Transactions where one or two large physician practices represent a significant share of revenue, or where the seller's personal relationships with clients are the primary retention mechanism.
Equity Rollover with Strategic or PE Acquirer
The seller receives a cash payment at close representing 80–90% of deal value and retains a 10–20% equity stake in the acquiring platform or newly formed entity. This structure is most common in private equity-backed roll-up acquisitions where the acquirer wants the seller engaged in geographic or specialty expansion post-close.
Pros
Cons
Best for: Experienced medical billing operators with specialty-specific expertise — such as anesthesia or behavioral health billing — who are attractive as operating partners in a regional or national RCM roll-up strategy.
Individual Operator Buying a Diversified Medical Billing Company via SBA 7(a)
$2,800,000
$2,520,000 SBA 7(a) loan (90%), $280,000 seller note (10%) subordinated and interest-only for 24 months at 6% per annum
Seller note matures at month 60 with a balloon payment. Buyer injects $280,000 in equity as SBA down payment requirement is waived under seller note injection rules. Seller transitions client relationships over a 90-day consulting period at $8,000 per month, included separately from purchase price. All client BAAs and payer enrollment agreements are assigned and updated at close.
PE-Backed RCM Roll-Up Acquiring a Specialty Billing Company with Client Concentration Risk
$4,200,000
$3,150,000 cash at close (75%), $1,050,000 earnout paid in two tranches of $525,000 at month 12 and month 24 contingent on retaining 90% of trailing twelve-month revenue and maintaining a net collection rate above 94%
Earnout metrics measured against a defined baseline revenue of $1,400,000 per year. If client retention falls below 85%, earnout is forfeited in full. Seller signs a 3-year non-compete covering physician billing services within the state. Seller remains as Director of Client Relations for 18 months at a market salary of $120,000 annually to support transition.
Regional RCM Platform Acquiring Owner-Operator Business with Equity Rollover
$3,600,000 implied enterprise value at 5.5x EBITDA
$2,880,000 cash at close (80%), $720,000 in equity rollover representing 8% ownership stake in the acquiring PE-backed platform valued at $9,000,000
Rollover equity is subject to a 5-year hold with tag-along rights in a platform exit. Seller joins the acquirer's advisory board for 24 months. Drag-along provisions apply if the PE sponsor exits within the hold period. Seller's equity is subject to a ratchet provision allowing up to 10% ownership if platform EBITDA doubles within 36 months of close.
Find Medical Billing Company Businesses For Sale
Pre-screened targets ready for your deal structure — free to join.
The most common structure for individual buyers is an SBA 7(a) loan covering 80–90% of the purchase price combined with a seller note of 5–10% subordinated to the SBA debt. This structure allows buyers with healthcare administration backgrounds to acquire cash-flowing RCM businesses with limited equity injection while giving sellers a near-full cash exit at close. SBA lenders will require clean financials, a diversified client base, and documented HIPAA compliance before approving a loan on a medical billing acquisition.
Earnouts are used when a significant portion of the business's value depends on client relationships that belong personally to the seller, or when one or two large physician practices drive the majority of revenue. Since client contracts in medical billing are typically cancelable on 30–90 days' notice, buyers cannot verify revenue durability until after close. Tying 15–25% of the purchase price to 12–24 months of post-close client retention and collection rate performance protects the buyer from paying full price for revenue that walks out the door during the transition.
HIPAA exposure directly influences how buyers structure escrow holdbacks and representations and warranties. If due diligence reveals unsigned Business Associate Agreements, incomplete security risk assessments, or a history of payer audits, buyers will typically insist on a 5–10% escrow holdback for 18–24 months to cover potential regulatory fines, audit repayments, or remediation costs. In severe cases, buyers may require the seller to remediate compliance gaps before closing, delaying the transaction timeline.
Yes, but with restrictions. SBA 7(a) rules require that a seller note be on full standby — meaning no principal or interest payments — for the first 24 months after close when the note is used to meet the equity injection requirement. After the standby period, payments resume under the agreed terms. The seller note typically carries an interest rate of 5–7% and a maturity of 5–7 years. SBA lenders view seller participation as a sign of confidence in the business's continuity, which can help the loan get approved when client concentration or key-person risk is a concern.
Payer enrollment numbers, NPI registrations, and client Business Associate Agreements do not automatically transfer to a new owner. In an asset sale — the most common structure — the buyer must re-enroll with all payers under the new entity's tax ID, which can take 60–120 days and temporarily disrupt cash flow. Many deals include a transition services agreement allowing the seller's entity to continue submitting claims during the re-enrollment period. Client BAAs must be updated to reflect the new ownership, requiring signed amendments from all healthcare provider clients before close or immediately post-close to maintain HIPAA compliance.
Well-run medical billing companies with diversified client bases, clean compliance records, and net collection rates above 95% typically trade at 4.5x to 6x EBITDA. Businesses with client concentration risk, owner-dependent operations, or outdated technology may trade at 3.5x to 4.5x EBITDA. Specialty-specific billing expertise — particularly in high-complexity areas like anesthesia, behavioral health, or radiology — can push multiples toward the upper end of the range due to the switching costs and pricing power it creates. Deal structure also affects effective multiple: a 5x deal with a 20% earnout may net the seller closer to 4x if clients churn during the earnout period.
More Medical Billing Company Guides
More Deal Structure Guides
Find the right target, structure the deal, and close with confidence.
Create your free accountNo credit card required
For Buyers
For Sellers